Accession Number:

AD1095264

Title:

Cell Communication in Antiestrogen Resistance

Descriptive Note:

Technical Report,15 Sep 2018,14 Sep 2019

Corporate Author:

Virginia Polytechnic Institute and State University Blacksburg United States

Personal Author(s):

Report Date:

2019-10-01

Pagination or Media Count:

12.0

Abstract:

More women die from the estrogen receptor positive ER breast cancer subtype than from any other. The proportion of early ER recurrences 5 years since diagnosis approaches that for all triple-negative breast cancers alone. Late recurrences greater than 5 years after diagnosis, the result of dormancy, are most common in ER disease and can arise decades after the initial diagnosis. Since recurrent breast cancers have escaped the effects of endocrine therapies, and are lethal, we will study endocrine resistance Tamoxifen Fulvestrant. Our primary objective is to identify what drives breast cancer growth and determine how to stop it. We will learn about why some breast cancers are aggressive and others are indolent, and whyhow some breast cancers lay dormant for years and then re-emerge.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE